News & Events

  • Anima Biotech achieves milestone in Takeda collaboration

    When: Jul. 20th, 2022

    Anima Biotech announced that the company has achieved a milestone in its collaboration with Takeda. 

    The milestone relates to one of the two newly initiated programs as part of the multi-target collaboration. This achievement entitles Anima to an undisclosed milestone payment.

    Anima Biotech and Takeda entered in the collaboration in March 2021 to discover and develop a new class of medicines for genetically-defined neurological diseases. Under the terms of the agreement, Anima Biotech used its mRNA Lightning platform to discover novel mRNA translation modulators against the collaboration targets. The collaboration also includes Anima’s Huntington’s Disease program against the HTT mutated protein.

    Download Press Release »

  • Oxford Global Discovery Europe

    When: Jun. 9th, 2022 to Jun. 10th, 2022
    Where: Berlin, Germany

    Anima Biotech has been invited to participate in the Oxford Global Discovery Europe Summit.
    Our Co-Founder and Chief Scientific Officer, Iris Alroy, Ph.D., will participate in a panel discussion titled, “Targeting The RNA As a Modality,” on June 9, 2022, at 2:10 p.m. CEST.
    Anima’s Technology Lead, Yoni Sheinberger, Ph.D., will also give a presentation titled, “Unlocking mRNA biology target space by combining biology with AI/ML mRNA image analysis,” taking place on June 9th at 5:15 p.m. CEST.
    The Oxford Global Discovery Europe Summit will bring together leading experts in the fields of Organoid Discovery, Phenotypic Screening, Targeted Protein Degradation, AI Computational Drug Design and Lead Optimization.

     

    Visit the conference website »

  • Cambridge Healthtech Institute’s 3rd Annual RNA-Targeting Small Molecule Drugs

    When: Apr. 20th, 2022 to Apr. 21st, 2022
    Where: San Diego, CA & online

    Anima Biotech’s Co-Founder and Chief Scientific Officer, Iris Alroy, Ph.D. will provide a presentation, titled, “mRNA Lightning Platform: A novel Platform for the Discovery of Small Molecule mRNA Drugs,” at the 3rd Annual RNA-Targeting Small Molecule Drugs: Novel Approaches to Modulate RNA Binding, Interactions and Function being held virtually and in San Diego, CA on April 21, 2022, at 2:10 PM PT. The conference on RNA-Targeting Small Molecule Drugs will highlight some of the innovative approaches being pursued to find new small molecule drugs for modulating RNA for therapeutic intervention.

    Visit conference website »

  • Drug Discovery Webinar 2022

    When: Mar. 28th, 2022 to Mar. 30th, 2022

    Our Co-Founder and Chief Scientific Officer, Iris Alroy, Ph.D. has been invited to present, “mRNA translation monitoring as a new strategy in drug discovery,” during the Scholars International Webinar on Advances in Drug Discovery and Development on March 29th, 11:35-12:10 GMT. The Drug Discovery Webinar 2022 aims to bring together renowned researchers, scientists and scholars to exchange and share their experiences on all aspects of chemistry, drug discovery, and drug design with a focus on the latest advancements in the drug discovery and development process.

    Visit the conference website »

  • 5th Annual Neuroscience Innovation Forum

    When: Mar. 22nd, 2022 to Mar. 23rd, 2022

    Our Co-Founder and CEO, Yochi Slonim will participate in a roundtable discussion during the 5th Annual Neuroscience Innovation Forum for Business Development, Licensing and Investment hosted virtually by Sachs Associates. The Industry Roundtable: Latest Trends in Partnering and M&A Panel will take place on March 22nd, 2022, 8:50 AM ET. The roundtable features executives from various pharmaceutical companies and will discuss the future of mergers and acquisitions in the biotech industry. 

    Download Press Release »

    Visit the conference website »

  • RNA-Based Drugs and Vaccines Innovation Summit

    When: Mar. 12th, 2022

    Anima Biotech’s CSO, Iris Alroy, Ph.D. has been invited to present at the RNA-Based Drugs and Vaccines Innovation Summit hosted by the International Science and Technology Conference Institute on March 12, 2022.

    Through Reviewing the progress and achievements of RNA drugs, this forum will build a communication platform for scientific researchers and peers to deepen academic exchanges and industrialization discussion and promote the research and development of RNA drugs and vaccines.

    Download Press Release »

    Visit the conference website »

  • 15th Drug Discovery Innovation Program

    When: Mar. 2nd, 2022

    Anima Biotech’s CSO, Iris Alroy, Ph.D. will serve as chair and give a presentation titled, “Paving the Way-RNA Therapeutics on the Rise” on March 2, 2022, 14:35 CET, during the 15th Drug Discovery Innovation Program.

    The event will focus on new technologies and innovative processes that are fundamentally changing what drug discovery research will look like in the next two to five years. This year’s Drug Discovery Innovation Programme will highlight the challenges discovery pipelines have faced due to COVID-19 and will put a spotlight on the adoption of technology to combat these.

    Visit the conference website »

  • 3rd RAS/MAPK Pathway Targeted Drug Discovery Summit

    When: Feb. 22nd, 2022 to Feb. 24th, 2022

    Anima Biotech’s CSO, Iris Alroy, Ph.D. has been invited to present on “Anima’s pan-KRAS mRNA translation modulators in mKRAS driven tumors” on February 24th 10:15 am EST with a live Q&A following the talk. The RAS/MAPK Pathway Target Drug Discovery Summit features 150+ experts in drug discovery, cancer biology, and medicinal chemistry, providing an exciting opportunity to learn more about the future of drugging the RAS/MAPK pathway and highlighting advancements in screening platforms, target identification, and emerging pipelines.

    Download Press Release »

    Visit the conference website »

  • 4th RNA-Targeted Drug Discovery Summit

    When: Dec. 7th, 2021 to Dec. 9th, 2021

    Anima Biotech has been invited to present an overview of its mRNA Lightning platform during the 4th annual RNA-Targeted Drug Discovery Summit. Anima Vice President of Research and Development, Iris Alroy, Ph.D. Will give a presentation titled, “Targeting mRNA Biology in a Tissue Selective & Disease-Specific Manner with Small Molecules” on Thursday, December 9th at 12:15 p.m. ET. In addition, Yochi Slonim, Co-founder and CEO of Anima Biotech will participate in a Fireside Chat & Networking Session titled, “Biopharma & Investment Partnering – Discussing the Future Landscape of Investment & Collaborations for RNA Small Molecule Space” on Thursday, December 9th at 1:30 p.m. ET. The session is dedicated to shining a spotlight onto the advantages and challenges of biopharma partnering and opening the floor to discussions with peers surrounding experiences with partnering and facilitating industry connections.

    The 4th RNA-Targeted Drug Discovery Summit will be an opportunity for thought leaders and experts in the biology and chemistry of RNA therapeutics to discuss cutting-edge small molecule strategies capable of interacting with and modulating RNA with improved specificity, selectivity and drug-like properties. Over 150+ biopharmaceutical representatives will lead conversations showcasing techniques to successfully translate RNA-targeted small molecule drugs that realize the full potential of this up-and-coming field.

    Download Press Release »

    Visit the conference website »

  • Elrig UK’s Drug Discovery 2021

    When: Oct. 19th, 2021 to Oct. 20th, 2021

    Anima Biotech has been invited to present at Elrig UK’s Drug Discovery 2021 meeting, taking place in Liverpool, U.K. Iris Alroy, Ph.D., Vice President of Research and Development at Anima Biotech, will give a presentation titled, “mRNA Lightning platform for the discovery of selective small molecule mRNA regulatory drugs.” Elrig’s annual Drug Discovery meeting is one of Europe’s largest gatherings for life science industry professionals and serves as a platform for the whole drug discovery community to re-connect with colleagues, re-invent the process of drug discovery and re-imagine a new vision for drug discovery.

    Visit the conference website »

Pages